Mather Group LLC. Acquires 2,389 Shares of Bristol-Myers Squibb (NYSE:BMY)

Mather Group LLC. raised its position in shares of Bristol-Myers Squibb (NYSE:BMY – Get Rating) by 62.8% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 6,192 shares of the biopharmaceutical company’s stock after buying an additional 2,389 shares during the quarter. Mather Group LLC.’s holdings in Bristol-Myers Squibb were worth $440,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of BMY. Dakota Wealth Management purchased a new position in shares of Bristol-Myers Squibb in the 1st quarter valued at approximately $332,000. Covestor Ltd raised its position in Bristol-Myers Squibb by 111.5% during the 1st quarter. Covestor Ltd now owns 2,052 shares of the biopharmaceutical company’s stock worth $150,000 after buying an additional 1,082 shares during the last quarter. NewEdge Advisors LLC raised its position in Bristol-Myers Squibb by 53.2% during the 1st quarter. NewEdge Advisors LLC now owns 165,336 shares of the biopharmaceutical company’s stock worth $12,075,000 after buying an additional 57,444 shares during the last quarter. Ergoteles LLC purchased a new position in Bristol-Myers Squibb during the 1st quarter worth approximately $1,997,000. Finally, Mackenzie Financial Corp raised its position in Bristol-Myers Squibb by 25.1% during the 1st quarter. Mackenzie Financial Corp now owns 338,563 shares of the biopharmaceutical company’s stock worth $24,725,000 after buying an additional 68,018 shares during the last quarter. 75.51% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities analysts have issued reports on the stock. Wells Fargo & Company raised their price target on shares of Bristol-Myers Squibb from $70.00 to $78.00 and gave the stock an “equal weight” rating in a research report on Tuesday, January 3rd. Cantor Fitzgerald started coverage on shares of Bristol-Myers Squibb in a research report on Tuesday, January 17th. They set an “overweight” rating and a $95.00 price target for the company. Morgan Stanley raised their price objective on shares of Bristol-Myers Squibb from $60.00 to $62.00 and gave the stock an “underweight” rating in a research note on Friday, February 3rd. Atlantic Securities raised their price objective on shares of Bristol-Myers Squibb from $88.00 to $90.00 and gave the stock an “overweight” rating in a research note on Friday, February 3rd. Finally, Jefferies Financial Group started coverage on shares of Bristol-Myers Squibb in a research note on Monday, March 6th. They set a “hold” rating and a $62.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $79.69.

Insider Buying and Selling at Bristol-Myers Squibb

In other news, CEO Giovanni Caforio sold 240,000 shares of Bristol-Myers Squibb stock in a transaction on Monday, February 6th. The stock was sold at an average price of $74.65, for a total transaction of $17,916,000.00. Following the transaction, the chief executive officer now owns 236,104 shares in the company, valued at approximately $17,625,163.60. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In related news, EVP Ann Powell sold 11,183 shares of the business’s stock in a transaction dated Monday, February 6th. The shares were sold at an average price of $74.69, for a total value of $835,258.27. Following the sale, the executive vice president now directly owns 23,043 shares in the company, valued at approximately $1,721,081.67. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Giovanni Caforio sold 240,000 shares of the business’s stock in a transaction dated Monday, February 6th. The shares were sold at an average price of $74.65, for a total transaction of $17,916,000.00. Following the completion of the sale, the chief executive officer now owns 236,104 shares in the company, valued at $17,625,163.60. The disclosure for this sale can be found here. 0.09% of the stock is currently owned by insiders.

Bristol-Myers Squibb Trading Up 0.7 %

Shares of BMY stock opened at $66.47 on Wednesday. The stock’s fifty day moving average is $71.29 and its two-hundred day moving average is $72.96. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.14 and a current ratio of 1.25. The firm has a market capitalization of $139.51 billion, a P/E ratio of 22.53, a PEG ratio of 1.43 and a beta of 0.46. Bristol-Myers Squibb has a fifty-two week low of $65.28 and a fifty-two week high of $81.43.

Bristol-Myers Squibb (NYSE:BMY – Get Rating) last announced its quarterly earnings data on Thursday, February 2nd. The biopharmaceutical company reported $1.82 earnings per share for the quarter, beating analysts’ consensus estimates of $1.71 by $0.11. The company had revenue of $11.41 billion for the quarter, compared to analyst estimates of $11.20 billion. Bristol-Myers Squibb had a return on equity of 51.60% and a net margin of 13.71%. The firm’s revenue for the quarter was down 4.8% on a year-over-year basis. During the same quarter last year, the firm posted $1.83 EPS. Research analysts expect that Bristol-Myers Squibb will post 8.07 earnings per share for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, May 1st. Shareholders of record on Monday, April 10th will be issued a $0.57 dividend. The ex-dividend date of this dividend is Thursday, April 6th. This represents a $2.28 dividend on an annualized basis and a yield of 3.43%. Bristol-Myers Squibb’s payout ratio is currently 77.29%.

Bristol-Myers Squibb Company Profile

(Get Rating)

Bristol Myers Squibb Co engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.